Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Monomer Protein
Catalog No: SURVIVIN-HB002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and LTLGEFLKL peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) & LTLGEFLKL).
Product Details
- Molecular Aliases
- Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.44 kDa. Due to glycosylation, the protein migrates to 52-65 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human HLA-A*02:01&B2M&Survivin (LTLGEFLKL) Monomer, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 10.9ng/ml determined by ELISA (QC Test).
Background
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target.
References
- (1) Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019 Apr 4;132(7):jcs223826. doi: 10.1242/jcs.223826. PMID: 30948431; PMCID: PMC6467487.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.